Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14week, randomized, double-blind, placebo-controlled trial
Diabetic Medicine, 01/03/2011Satoh J et al.
To evaluate the efficacy, safety and pharmacokinetics of pregabalin in treating neuropathic pain associated with diabetic peripheral neuropathy in Japanese patients. A randomized, double–blind, placebo–controlled, multicentre 14 week clinical trial was conducted. Pregabalin was well tolerated; somnolence (26%), dizziness (24%), peripheral oedema (13%) and weight gain (11%) were the most common adverse events and generally were reported as mild to moderate.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.